Blockade of angiotensin II attenuates VEGF-mediated blood-retinal barrier breakdown in diabetic retinopathy. - Wikidata - awgldk - TriplyDB

Blockade of angiotensin II attenuates VEGF-mediated blood-retinal barrier breakdown in diabetic retinopathy.

Blockade of angiotensin II attenuates VEGF-mediated blood-retinal barrier breakdown in diabetic retinopathy.

http://www.wikidata.org/entity/Q39901974

about

Alternative pathways in the development of diabetic retinopathy: the renin-angiotensin and kallikrein-kinin systems Vitreous mediators in retinal hypoxic diseases Inhibition of protein kinase C delta attenuates blood-retinal barrier breakdown in diabetic retinopathy.Effect of angiotensin II type 1 receptor blocker and angiotensin converting enzyme inhibitor on the intraocular growth factors and their receptors in streptozotocin-induced diabetic rats.Vascular dysfunction associated with type 2 diabetes and Alzheimer's disease: a potential etiological linkage.The development of blood-retinal barrier during the interaction of astrocytes with vascular wall cells.Validation of structural and functional lesions of diabetic retinopathy in mice Microvascular responses to cardiovascular risk factors.TNFalpha is required for late BRB breakdown in diabetic retinopathy, and its inhibition prevents leukostasis and protects vessels and neurons from apoptosis Adeno-Associated Virus Overexpression of Angiotensin-Converting Enzyme-2 Reverses Diabetic Retinopathy in Type 1 Diabetes in Mice.Non-traditional systemic treatments for diabetic retinopathy: an evidence-based review Animal models of diabetic retinopathy: summary and comparison.Advances in the medical treatment of diabetic retinopathy.Intracardiac renin-angiotensin system and myocardial repair/remodeling following infarction.Hypoxia-induced angiotensin II by the lactate-chymase-dependent mechanism mediates radioresistance of hypoxic tumor cells.Mediators of ocular angiogenesis.Inflammation in diabetic retinopathy.Diabetic microvascular complications: possible targets for improved macrovascular outcomes Neuropeptides and diabetic retinopathy.Hydration, fluid regulation and the eye: in health and disease.Recent perspectives on the delivery of biologics to back of the eye.Hypoxia-mediated retinal neovascularization and vascular leakage in diabetic retina is suppressed by HIF-1α destabilization by SH-1242 and SH-1280, novel hsp90 inhibitors.Role of Tissue Renin-angiotensin System and the Chymase/angiotensin-(1-12) axis in the Pathogenesis of Diabetic Retinopathy.Renin-Angiotensin system hyperactivation can induce inflammation and retinal neural dysfunction.Resveratrol blocks diabetes-induced early vascular lesions and vascular endothelial growth factor induction in mouse retinas.Decursin inhibits VEGF-mediated inner blood-retinal barrier breakdown by suppression of VEGFR-2 activation.Aliskiren decreases oxidative stress and angiogenic markers in retinal pigment epithelium cells.Effects of quercetin on the expression of MCP-1, MMP-9 and VEGF in rats with diabetic retinopathy.Small GTPase ARF6 controls VEGFR2 trafficking and signaling in diabetic retinopathy.Diabetic Retinopathy in the Spontaneously Diabetic Torii Rat: Pathogenetic Mechanisms and Preventive Efficacy of Inhibiting the Urokinase-Type Plasminogen Activator Receptor System.Relationship between G proteins coupled receptors and tight junctions.Investigation of barrier characteristics in the hyaloid-retinal vessel of zebrafish.The effect of a systemic angiotensin receptor blocker on vascular endothelial growth factor in the vitreous of patients with proliferative diabetic retinopathy.Angiotensin II receptor blocker improves the lowered exercise capacity and impaired mitochondrial function of the skeletal muscle in type 2 diabetic mice.Local angiotensin II contributes to tumor resistance to checkpoint immunotherapy

P2860

Q27025635-FE51025E-EB5E-4AA2-BF10-4886CEA81259 Q27028225-87EE53E7-6BB8-4C9B-9C9E-C68DE9092186 Q33703836-2399B933-CFB7-441A-9AED-9232E5AE86FD Q33914589-418A18D7-28D5-44A9-A6EF-798809A52DA6 Q34066200-7037ACE7-F61A-45B6-9C57-CC56CBE25D38 Q34096257-23576BF8-8E3D-453B-ADE0-626C3F0B9488 Q34364177-B7435BD8-6717-4DE1-8121-36023DC0AE22 Q34766422-01108668-213D-47CB-B2CF-5A8C524F1B78 Q35005977-7FE00B5B-20A3-4547-A67B-8BFC09418B98 Q36990241-23AB257E-035C-42CD-8A1B-B3D436CCF594 Q37204025-F3D6CE20-CBF1-4415-B888-1FCB98968E34 Q37304677-1C87F182-6F48-4AE6-9B5B-D52FE454B3A3 Q37564793-F637BE63-688A-4F29-9246-A42D1E4ED9BA Q37580070-FB51008D-5E90-4D52-937B-5D9753A4D284 Q37644348-1EFE0FEC-69C6-4093-8B0A-E381CF71B83A Q37678807-72B034EB-6217-4976-8793-FB9EF710E33D Q37884176-AAB0E17B-3994-492D-9CEC-0EE484DFEA41 Q37892915-7367B498-BD56-4947-8271-DF51F2CC79A1 Q38050159-E6C64C97-0C44-4806-99FC-88F3EA86BFAD Q38464030-71E2325F-0CE8-4539-8DBE-1675D18CBC1F Q38940171-F76529D7-6B0A-48CE-96D4-53CBB5962F91 Q38990297-3B880088-4447-4CA7-BB90-AB954C447E73 Q39238324-2535A47C-6821-4425-B880-34F13FCC1640 Q42098043-FEE7A92C-2FF2-4B93-924B-125E3357FFAB Q43442634-5F78977F-21C7-46FB-B6C9-E2011A624212 Q45964657-0CF231F4-8A60-447F-9F0B-07C5908C7244 Q46483060-059A7C08-30D8-4208-A34D-47885257707F Q47093719-BDB8A63B-BB14-40F2-B81C-B0CD34B17C2E Q48623673-73D16616-3B22-4774-9D27-B06C4E02979E Q49724247-3FD616BB-5F08-4C72-8A03-A8492D3FA4DD Q50116104-6C894309-8A2D-4ADB-BB09-6B82F9150122 Q50524854-1A1F4B2F-FA12-4A16-8A93-E2FDC22AE74E Q50947386-CD30F26D-438C-47E0-9398-63B5A2F6F5F2 Q53124062-8F61B5BC-452C-4F66-8C72-43F350C32F71 Q58748151-BFBAF697-B8F8-43DE-837D-AAEFD5E4B756

P2860

Blockade of angiotensin II attenuates VEGF-mediated blood-retinal barrier breakdown in diabetic retinopathy.

http://www.wikidata.org/entity/Q39901974

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh

2008年學術文章

@zh-hant

name

Blockade of angiotensin II att ...... kdown in diabetic retinopathy.

@en

Blockade of angiotensin II att ...... kdown in diabetic retinopathy.

@nl

type

label

Blockade of angiotensin II att ...... kdown in diabetic retinopathy.

@en

Blockade of angiotensin II att ...... kdown in diabetic retinopathy.

@nl

prefLabel

Blockade of angiotensin II att ...... kdown in diabetic retinopathy.

@en

Blockade of angiotensin II att ...... kdown in diabetic retinopathy.

@nl

P1433

Q39901974-112D804C-C62B-4369-A766-5A637C22E7CC

P1476

Q39901974-8D744B6E-B404-44D9-A10A-EE07DDE16AD0

P2093

Q39901974-065BE51F-CB85-42DF-9244-1AEF67A5B0BE

Q39901974-222E5F1C-1867-4A77-8B64-94C8C98F42B2

Q39901974-275A0D25-6E4C-4847-AB75-A1350B855747

Q39901974-2C59ECED-6056-4BEC-9055-D6DEF6629447

Q39901974-AF65D999-4F56-48DF-9CF3-6AAB9F6E6E52

P2860

Q39901974-0166017E-9574-407D-B4E4-C4D27996253F

Q39901974-0E7BE4C3-3121-41D5-81B5-26F99C8D4CF8

Q39901974-2F88C5B8-1174-41B8-8B1F-FC6CA39D9BD8

Q39901974-39A5ECFC-A307-440D-A260-5454948549E6

Q39901974-427373F6-8750-47FE-BEAB-071D9049A2D4

Q39901974-4880C190-3B1C-4108-9AF2-EE5F189AB04F

Q39901974-5FDF04AB-0065-415D-A166-28F1E2DD0827

Q39901974-60D8E468-D08A-4BCC-BC7A-00689B6C1C85

Q39901974-80F824BC-2606-4770-9A68-E24C3AA18F3A

Q39901974-876DD277-1356-44F4-862E-EE349BAB37F2

P304

Q39901974-C126F9E9-E5EF-4F68-A255-55247021BF21

P31

Q39901974-3C126555-B035-4416-AA94-8E8D00DC9419

P356

Q39901974-3EB903D6-F548-4BF2-963B-6E13D5924B61

P433

Q39901974-B9B91E0D-1B73-4551-9B98-04FB09651D5D

P478

Q39901974-D978343C-7A3A-4F47-AE0D-A37EAC882089

P577

Q39901974-ADFF4F9D-F98F-4E5B-9238-B6B9EFF65FC2

P5875

Q39901974-5BDF6C1D-0C77-4211-9590-683A68CDD6DA

P698

Q39901974-EF5FB540-8EBD-417D-A083-2A1F24B1AD18

P356

P1433

Journal of Cerebral Blood Flow & Metabolism

P1476

Blockade of angiotensin II att ...... kdown in diabetic retinopathy.

@en

P2093

Chang Sik Cho

http://www.w3.org/2001/XMLSchema#string

Jeong Hun Kim

http://www.w3.org/2001/XMLSchema#string

Jin Hyoung Kim

http://www.w3.org/2001/XMLSchema#string

Kyu-Won Kim

http://www.w3.org/2001/XMLSchema#string

Young Suk Yu

http://www.w3.org/2001/XMLSchema#string

P2860

Proangiogenic effect of angiotensin-converting enzyme inhibition is mediated by the bradykinin B(2) receptor pathway.

How the diabetic eye loses vision.

Angiotensin AT(1) and AT(2) receptors differentially regulate angiopoietin-2 and vascular endothelial growth factor expression and angiogenesis by modulating heparin binding-epidermal growth factor (EGF)-mediated EGF receptor transactivation.

Molecular mechanisms of vascular permeability in diabetic retinopathy.

SSeCKS regulates angiogenesis and tight junction formation in blood-brain barrier.

Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.

Early cellular and molecular changes induced by diabetes in the retina.

Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate.

Perindopril: possible use in cancer therapy.

Retinal angiogenesis is mediated by an interaction between the angiotensin type 2 receptor, VEGF, and angiopoietin

P304

621-628

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/JCBFM.2008.154

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P577

2008-12-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23688803

http://www.w3.org/2001/XMLSchema#string

P698

19107135

http://www.w3.org/2001/XMLSchema#string